{"id":1218,"date":"2018-01-29T18:05:22","date_gmt":"2018-01-29T17:05:22","guid":{"rendered":"http:\/\/haavind.local\/en\/2018\/01\/29\/pharma-report-2018\/"},"modified":"2022-07-21T12:51:25","modified_gmt":"2022-07-21T12:51:25","slug":"pharma-report-2018","status":"publish","type":"post","link":"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-2018\/","title":{"rendered":"Pharma Report Winter 2018 from Haavind"},"content":{"rendered":"\t<div class=\"template-post alignwide wp-block-dekode-hero\">\n\t\t<div class=\"hero__inner\">\n\t\t\t<div class=\"hero__inner_blocks\">\n\t\t\t\t<h1 class=\"wp-block-post-title\">Pharma Report Winter 2018 from Haavind<\/h1>\n\n<p>We are once again proud to present the newest edition of our biannual pharma report. The report looks more closely at some of the legal developments in the pharmaceutical sector in Norway, which occurred in the second part of 2017.<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<div><\/div>\n\t\t\t\t\t<div class=\"post-meta\">\n\t\t\t\t\t\t<span class=\"info-small\">29 January, 2018 \u00b7 2 min. reading time<\/span>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\n<div class=\"alignleft wp-block-haavind-byline\">\n\t\t\t\t<span class=\"author-tag\">Written by<\/span>\n\t\t\t\t<div class=\"authors\"><a href=\"https:\/\/haavind.stage01.dekodes.no\/en\/people\/vebjorn-krag-iversen\/\" class=\"t2-byline__author-link\">\n\t\t\t\t\t<div class=\"author-inner\">\n\t\t\t\t\t\t<img decoding=\"async\" src=\"https:\/\/haavind.stage01.dekodes.no\/content\/uploads\/sites\/2\/2016\/04\/Vebjorn-Iversen-233x300.jpg\" \/>\n\t\t\t\t\t\t<div>\n\t\t\t\t\t\t<span class=\"name\">Vebj\u00f8rn Krag Iversen<\/span>\n\t\t\t\t\t\t<span>Partner<\/span>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/a><a href=\"https:\/\/haavind.stage01.dekodes.no\/en\/people\/hakon-austdal\/\" class=\"t2-byline__author-link\">\n\t\t\t\t\t<div class=\"author-inner\">\n\t\t\t\t\t\t<img decoding=\"async\" src=\"https:\/\/haavind.stage01.dekodes.no\/content\/uploads\/sites\/2\/2016\/04\/Ha\u030akon-Austdal-233x300.jpg\" \/>\n\t\t\t\t\t\t<div>\n\t\t\t\t\t\t<span class=\"name\">H\u00e5kon Austdal<\/span>\n\t\t\t\t\t\t<span>Specialist Counsel<\/span>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/a><\/div>\n\t\t\t\t<div class=\"topics\">\n\t\t\t\t<span>Topics<\/span>\n\t\t\t\t<div><span class=\"tag-link\">Intellectual property rights<\/span><span class=\"tag-link\">Healthcare and life science<\/span><\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n<p>We are once again proud to present the newest edition of our biannual pharma report. The report looks more closely at some of the legal developments in the pharmaceutical sector in Norway, which occurred in the second part of 2017.<\/p>\n\n\n<p>In this edition, you can read about several patent cases, including the buprenorphine case which involved practitioners from our law firm. You can also find out whether GlaxoSmithKline succeeded in acquiring trademark protection for the color purple. In addition, you can read about the Norwegian Board of Health Supervision\u2019s take on off-label practice, as well as other regulatory developments.<\/p>\n\n\n\n<p><a href=\"https:\/\/indd.adobe.com\/view\/47ed067d-0004-4500-9cbe-d0c129a5f087\"><strong>Read the Pharma Report Winter 2018 here (e-book)<\/strong><\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/haavind.stage01.dekodes.no\/content\/uploads\/sites\/2\/2018\/01\/Haavind-Pharma-Report-January-2018.pdf\"><strong>Download the Pharma Report Winter 2018 here (PDF, 12MB)<\/strong><\/a><\/p>\n\n\n\n<p>Our Healthcare and Life Science team continuously and closely monitors legal developments in Norway relevant for the pharmaceutical sector. If you wish to discuss how your business can meet the legal challenges of this innovative and highly regulated sector, you are always welcome to contact us.<\/p>\n\n\n<div class=\"wp-block-image\"><figure class=\"alignleft\"><img loading=\"lazy\" decoding=\"async\" width=\"1920\" height=\"640\" src=\"https:\/\/haavind.stage01.dekodes.no\/content\/uploads\/sites\/2\/2022\/06\/1920x640life-science.jpg\" alt=\"\" class=\"wp-image-2360\" title=\"1920x640_life science\" srcset=\"https:\/\/haavind.stage01.dekodes.no\/content\/uploads\/sites\/2\/2022\/06\/1920x640life-science.jpg 1920w, https:\/\/haavind.stage01.dekodes.no\/content\/uploads\/sites\/2\/2022\/06\/1920x640life-science-300x100.jpg 300w, https:\/\/haavind.stage01.dekodes.no\/content\/uploads\/sites\/2\/2022\/06\/1920x640life-science-1024x341.jpg 1024w, https:\/\/haavind.stage01.dekodes.no\/content\/uploads\/sites\/2\/2022\/06\/1920x640life-science-768x256.jpg 768w, https:\/\/haavind.stage01.dekodes.no\/content\/uploads\/sites\/2\/2022\/06\/1920x640life-science-1536x512.jpg 1536w\" sizes=\"(max-width: 1920px) 100vw, 1920px\" \/><\/figure><\/div>\n","protected":false},"excerpt":{"rendered":"<p>We are once again proud to present the newest edition of our biannual pharma report. The report looks more closely at some of the legal developments in the pharmaceutical sector in Norway, which occurred in the second part of 2017.<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"sector":[7],"speciality":[24],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.2 (Yoast SEO v24.2) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma Report Winter 2018 from Haavind - Haavind EN<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-2018\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma Report Winter 2018 from Haavind\" \/>\n<meta property=\"og:description\" content=\"We are once again proud to present the newest edition of our biannual pharma report. The report looks more closely at some of the legal developments in the pharmaceutical sector in Norway, which occurred in the second part of 2017.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-2018\/\" \/>\n<meta property=\"og:site_name\" content=\"Haavind EN\" \/>\n<meta property=\"article:published_time\" content=\"2018-01-29T17:05:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-21T12:51:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/haavind.stage01.dekodes.no\/content\/uploads\/sites\/2\/2022\/06\/1920x640life-science.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-2018\/\",\"url\":\"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-2018\/\",\"name\":\"Pharma Report Winter 2018 from Haavind - Haavind EN\",\"isPartOf\":{\"@id\":\"https:\/\/haavind.stage01.dekodes.no\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-2018\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-2018\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/haavind.stage01.dekodes.no\/content\/uploads\/sites\/2\/2022\/06\/1920x640life-science.jpg\",\"datePublished\":\"2018-01-29T17:05:22+00:00\",\"dateModified\":\"2022-07-21T12:51:25+00:00\",\"author\":{\"@id\":\"\"},\"breadcrumb\":{\"@id\":\"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-2018\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-2018\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-2018\/#primaryimage\",\"url\":\"https:\/\/haavind.stage01.dekodes.no\/content\/uploads\/sites\/2\/2022\/06\/1920x640life-science.jpg\",\"contentUrl\":\"https:\/\/haavind.stage01.dekodes.no\/content\/uploads\/sites\/2\/2022\/06\/1920x640life-science.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-2018\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Intellectual property rights\",\"item\":\"https:\/\/haavind.stage01.dekodes.no\/en\/kompetanse\/fagomrade\/ipr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharma Report Winter 2018 from Haavind\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/haavind.stage01.dekodes.no\/en\/#website\",\"url\":\"https:\/\/haavind.stage01.dekodes.no\/en\/\",\"name\":\"Haavind EN\",\"description\":\"-\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/haavind.stage01.dekodes.no\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma Report Winter 2018 from Haavind - Haavind EN","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-2018\/","og_locale":"en_US","og_type":"article","og_title":"Pharma Report Winter 2018 from Haavind","og_description":"We are once again proud to present the newest edition of our biannual pharma report. The report looks more closely at some of the legal developments in the pharmaceutical sector in Norway, which occurred in the second part of 2017.","og_url":"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-2018\/","og_site_name":"Haavind EN","article_published_time":"2018-01-29T17:05:22+00:00","article_modified_time":"2022-07-21T12:51:25+00:00","og_image":[{"url":"https:\/\/haavind.stage01.dekodes.no\/content\/uploads\/sites\/2\/2022\/06\/1920x640life-science.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-2018\/","url":"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-2018\/","name":"Pharma Report Winter 2018 from Haavind - Haavind EN","isPartOf":{"@id":"https:\/\/haavind.stage01.dekodes.no\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-2018\/#primaryimage"},"image":{"@id":"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-2018\/#primaryimage"},"thumbnailUrl":"https:\/\/haavind.stage01.dekodes.no\/content\/uploads\/sites\/2\/2022\/06\/1920x640life-science.jpg","datePublished":"2018-01-29T17:05:22+00:00","dateModified":"2022-07-21T12:51:25+00:00","author":{"@id":""},"breadcrumb":{"@id":"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-2018\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-2018\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-2018\/#primaryimage","url":"https:\/\/haavind.stage01.dekodes.no\/content\/uploads\/sites\/2\/2022\/06\/1920x640life-science.jpg","contentUrl":"https:\/\/haavind.stage01.dekodes.no\/content\/uploads\/sites\/2\/2022\/06\/1920x640life-science.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-2018\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Intellectual property rights","item":"https:\/\/haavind.stage01.dekodes.no\/en\/kompetanse\/fagomrade\/ipr\/"},{"@type":"ListItem","position":2,"name":"Pharma Report Winter 2018 from Haavind"}]},{"@type":"WebSite","@id":"https:\/\/haavind.stage01.dekodes.no\/en\/#website","url":"https:\/\/haavind.stage01.dekodes.no\/en\/","name":"Haavind EN","description":"-","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/haavind.stage01.dekodes.no\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/posts\/1218"}],"collection":[{"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/comments?post=1218"}],"version-history":[{"count":1,"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/posts\/1218\/revisions"}],"predecessor-version":[{"id":3771,"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/posts\/1218\/revisions\/3771"}],"wp:attachment":[{"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/media?parent=1218"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/categories?post=1218"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/tags?post=1218"},{"taxonomy":"sector","embeddable":true,"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/sector?post=1218"},{"taxonomy":"speciality","embeddable":true,"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/speciality?post=1218"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}